Compare GSK plc (GSK) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Nutanix Inc — how do they compare? GSK plc trades at $52.65 (market cap $101.34B), while Nutanix Inc trades at $56.01 (market cap $14.76B). The key difference: GSK plc is far larger — about 6.9× Nutanix Inc's market cap, and GSK plc pays a 3.49% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals.
| GSK | NTNX | |
|---|---|---|
Market Cap | $101.34B | $14.76B |
Sector | Health | Technology |
52-Week High | $61.18 | $81.12 |
52-Week Low | $36.20 | $34.41 |
Enterprise Value | $121.95B | $14.27B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Nutanix (NTNX) trades at $56.09, up 1.12% with a bullish technical outlook and strong fundamental momentum. The stock exhibits robust earnings beats, with Q1 2026 EPS of $0.47 surpassing the $0.36 estimate, and revenue growth projected to $2.7B in 2026. Analyst sentiment is positive with a $57.80 consensus target, and recent news highlights AI infrastructure advancements, including NVIDIA certification for Nutanix Unified Storage.
The outlook for NTNX is favorable, driven by consistent earnings outperformance and strategic positioning in hybrid cloud computing. Key risks include high valuation multiples and competitive pressures. Investment opportunity lies in sustained execution and AI-driven growth, though investors should monitor margin sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
